财报披露
Kamada(KMDA)03-06 20:15
$Kamada(KMDA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-020275 Act: 34 Size: 4 MB 网页链接
简介:Kamada Ltd.是一家通过销售市场现有罕见组合药物产品的,等离子体衍生蛋白质疗法公司。公司开发和生产的专业衍化蛋白质疗法产品,在一些新兴市场上,这些产品通过美洲和欧洲的战略合作伙伴被经营出售,或者通过当地的经销商直接在当地销售,该公司的旗舰产品是“Glassia”。 卡曼达公司专利产品在两个领域经营操作:专利产品领域—公司发展和制造衍生蛋白质疗法产品并且在超过15个国家里对其进行营销;分销领域—在以色列,公司通过关键的途径分销由第三方生产的药物,这些药物大部分由等离子体及其衍生品组成。1990年12月13日,公司在以色列成立,名称为 Kamada有限公司。
今开:5.2 | 昨收:5.2 |
最高:5.2 | 最低:5.12 |
涨停价: | 跌停价: |
总市值:296019569 |
Kamada(KMDA)03-06 20:15
$Kamada(KMDA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-020275 Act: 34 Size: 4 MB 网页链接
Kamada(KMDA)02-28 20:05
$Kamada(KMDA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-017739 Act: 34 Size: 19 KB 网页链接
Kamada(KMDA)02-15 06:05
$Kamada(KMDA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001213900-24-014144 Act: 34 Size: 78 KB 网页链接
Kamada(KMDA)03-06 20:05
$Kamada(KMDA)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001213900-24-020272 Act: 34 Size: 18 MB 网页链接
Kamada(KMDA)02-13 01:45
$Kamada(KMDA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001178913-24-000467 Act: 34 Size: 79 KB 网页链接
逍遥投资派2023-05-21 00:00
$Kamada(KMDA)$ 5年来营收基本在1亿以上窄幅波动,营业利润则在2021年突然转亏,2022年也仅恢复到2020年的1/4,净利润近两年则连续小幅亏损。
目前市值2.2亿,即使以2018年最高的0.22亿净利润计算,市盈率也达到了10,缺乏吸引力。查看全文
平凡Stone2021-02-20 23:48
$Kamada(KMDA)$ 低价优质股,爆发可期。查看全文
平凡Stone2021-02-03 23:06
$Kamada(KMDA)$ ARK fund Israel
Kamada Ltd.是一家通过销售市场现有罕见组合药物产品的,等离子体衍生蛋白质疗法公司。公司开发和生产的专业衍化蛋白质疗法产品,在一些新兴市场上,这些产品通过美洲和欧洲的战略合作伙伴被经营出售,或者通过当地的经销商直接在当地销售,该公司的旗舰产品是“...查看全文
令狐不冲9992020-08-24 21:07
8.24盘前异动: $Kamada(KMDA)$ $T2 Biosystems(TTOO)$ $Zymeworks(ZYME)$查看全文
牛唐2020-08-24 16:49
免疫球蛋白疗法集体爆发$Adma生物制品(ADMA)$ $Kamada(KMDA)$ $拼多多(PDD)$查看全文
尨三2020-08-24 16:44
$Kamada(KMDA)$盘前拉升,啥情况查看全文
一年交易一次2020-02-06 07:39
$Kamada(KMDA)$ Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2019, prior to the open of the U.S. financial markets on Wedne...查看全文
Harry_汪2016-09-26 23:09
$Kamada(KMDA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-020275 Act: 34 Size: 4 MB 网页链接
$Kamada(KMDA)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001213900-24-020272 Act: 34 Size: 18 MB 网页链接
$Kamada(KMDA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-017739 Act: 34 Size: 19 KB 网页链接
$Kamada(KMDA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001213900-24-014144 Act: 34 Size: 78 KB 网页链接
$Kamada(KMDA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001178913-24-000467 Act: 34 Size: 79 KB 网页链接
$Kamada(KMDA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001178913-23-003994 Act: 34 Size: 82 KB 网页链接
$Kamada(KMDA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-099085 Act: 34 Size: 13 KB 网页链接
$Kamada(KMDA)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001178913-23-003931 Act: 34 Size: 78 KB 网页链接
$Kamada(KMDA)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-093276 Act: 34 Size: 85 KB 网页链接
$Kamada(KMDA)$ 6-K/A [Amend] Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-085652 Act: 34 Size: 407 KB 网页链接